![](https://www.precisionformedicine.com/hs-fs/hubfs/Clinical%20Trial%20Landscape%20-%20Radiopharmaceuticals.png?width=396&height=224&name=Clinical%20Trial%20Landscape%20-%20Radiopharmaceuticals.png)
![Andy, Kinley Avatar](https://www.precisionformedicine.com/hs-fs/hubfs/PfM%20Website/Headshots/Headshots%20no%20background/AndyKinley_headshot.png?width=100&height=100&name=AndyKinley_headshot.png)
Andy Kinley
Andy Kinley, Ph.D. is Vice President of Innovation and Clinical Science at Precision for Medicine. He is a clinical researcher with over 25 years of combined experience leading basic and clinical research in oncology and hematology. His early scientific career focused on cancer cell signaling, setting a foundation to complement his clinical research roles in trial design and implementation of effective strategies for oncology clinical trials. Andy specializes in immuno-oncology trials (checkpoint inhibitors, T-cell agonists, bispecifics, cytokines, oncolytic viruses, neoantigen cancer vaccines), including autologous and allogeneic adoptive cell therapies (CAR-T, TCR, TIL, NK cells). Today, Andy identifies and implements innovative tools, datasets, and services that can impact clinical trial execution including quality, patient diversity, site identification, and trial timelines.
-
Read: Clinical Trial Landscape: Radiopharmaceuticals Clinical Trial Landscape: Radiopharmaceuticals
-
Read: Clinical Trial Landscape: Acute Myeloid Leukemia (AML) Discover
-
Read: Clinical Trial Landscape: Breast Cancer Discover
-
Read: Clinical Trial Landscape: Cell Therapies Discover
-
Read: Clinical Trial Landscape: Non-small Cell Lung Cancer (NSCLC) Discover
-
Read: Driving Oncology Trial Execution with Novel Data-Driven Approaches to Site and Patient Identification Driving Oncology Trial Execution with Novel Data-Driven Approaches to Site and Patient Identification
| -
Read: Next in Gene Therapy: Trends, Innovations, and Challenges Clinical Trials - Manufacturing - Gene Therapies
Next in Gene Therapy: Trends, Innovations, and Challenges
| -
Read: Increased Complexity and Therapeutic Combinations Pave the Way in Immuno-oncology Increased Complexity and Therapeutic Combinations Pave the Way in Immuno-oncology
| -
Read: Streamlining Recruitment in Biomarker-driven Oncology and Rare Disease Studies Biomarkers - Oncology - Rare Diseases
Streamlining Recruitment in Biomarker-driven Oncology and Rare Disease Studies
|